Morphosys Ag Adr Stock Buy Hold or Sell Recommendation
| MOR Stock | USD 18.04 0.09 0.50% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding MorphoSys AG ADR is 'Strong Sell'. Macroaxis provides MorphoSys buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MOR positions. The advice algorithm takes into account all of MorphoSys' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting MorphoSys' buy or sell advice are summarized below:
Real Value 13.25 | Target Price 13.2 | Hype Value 17.98 | Market Value 18.04 | Naive Value 17.26 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell MorphoSys AG ADR given historical horizon and risk tolerance towards MorphoSys. When Macroaxis issues a 'buy' or 'sell' recommendation for MorphoSys AG ADR, the advice is generated through an automated system that utilizes algorithms and statistical models.
MorphoSys |
Execute MorphoSys Buy or Sell Advice
The MorphoSys recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on MorphoSys AG ADR. Macroaxis does not own or have any residual interests in MorphoSys AG ADR or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute MorphoSys' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
MorphoSys Trading Alerts and Improvement Suggestions
| MorphoSys AG ADR is way too risky over 90 days horizon | |
| MorphoSys AG ADR appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 238.28 M. Reported Net Loss for the year was (189.73 M) with profit before taxes, overhead, and interest of 229.65 M. | |
| MorphoSys AG ADR has about 726.83 M in cash with (295.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32. | |
| MorphoSys AG ADR has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from zacks.com: Novartis Inks Deal for ARVNs Prostate Cancer Candidate |
MorphoSys Returns Distribution Density
The distribution of MorphoSys' historical returns is an attempt to chart the uncertainty of MorphoSys' future price movements. The chart of the probability distribution of MorphoSys daily returns describes the distribution of returns around its average expected value. We use MorphoSys AG ADR price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of MorphoSys returns is essential to provide solid investment advice for MorphoSys.
| Mean Return | 1.39 | Value At Risk | -5.21 | Potential Upside | 9.51 | Standard Deviation | 8.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of MorphoSys historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
MorphoSys Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MorphoSys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MorphoSys AG ADR backward and forwards among themselves. MorphoSys' institutional investor refers to the entity that pools money to purchase MorphoSys' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 269 K | Group One Trading, Lp | 2023-12-31 | 256.5 K | Cubist Systematic Strategies, Llc | 2023-12-31 | 196.2 K | Two Sigma Investments Llc | 2023-12-31 | 185.9 K | Point72 Asset Management, L.p. | 2023-09-30 | 174.8 K | Hap Trading, Llc | 2023-12-31 | 161.5 K | Verition Fund Managegment, Llc | 2023-12-31 | 149.7 K | Opaleye Management Inc | 2023-12-31 | 145 K | Citadel Advisors Llc | 2023-09-30 | 133.3 K | T. Rowe Price Investment Management,inc. | 2023-12-31 | 6.4 M | Kynam Capital Management, Lp | 2023-12-31 | 4.2 M |
MorphoSys Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.1M) | 65.5M | 13.5M | 279.1M | (243.9M) | (231.7M) | |
| Free Cash Flow | (83.8M) | (14.1M) | (507.6M) | (381.9M) | (298.7M) | (283.8M) | |
| Depreciation | 6.2M | 8.3M | 10.1M | 10.5M | 10.5M | 6.0M | |
| Other Non Cash Items | (4.4M) | (17.3M) | 209.9M | (347.0M) | (150.0M) | (142.5M) | |
| Capital Expenditures | 3.7M | 49.3M | 26.2M | 15.2M | 2.9M | 2.7M | |
| Net Income | (103.0M) | 97.9M | (514.5M) | (151.1M) | (189.7M) | (180.2M) | |
| End Period Cash Flow | 44.3M | 109.8M | 123.2M | 402.4M | 158.5M | 85.1M | |
| Change To Inventory | (4.1M) | (8.5M) | (30.3M) | 44.3M | 50.9M | 53.5M | |
| Investments | 78.6M | (879.6M) | 403.6M | 345.0M | 15.4M | 16.1M | |
| Net Borrowings | 1.4M | 317.9M | (3.1M) | (3.4M) | (3.9M) | (3.7M) | |
| Change To Netincome | (2.1M) | (83.8M) | 135.9M | (174.7M) | (157.3M) | (149.4M) |
MorphoSys Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to MorphoSys or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that MorphoSys' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a MorphoSys stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 1.47 | |
β | Beta against NYSE Composite | -1.9 | |
σ | Overall volatility | 7.58 | |
Ir | Information ratio | 0.16 |
MorphoSys Volatility Alert
MorphoSys AG ADR is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure MorphoSys' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact MorphoSys' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.MorphoSys Fundamentals Vs Peers
Comparing MorphoSys' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze MorphoSys' direct or indirect competition across all of the common fundamentals between MorphoSys and the related equities. This way, we can detect undervalued stocks with similar characteristics as MorphoSys or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of MorphoSys' fundamental indicators could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare MorphoSys to competition |
| Fundamentals | MorphoSys | Peer Average |
| Return On Equity | -1.84 | -0.31 |
| Return On Asset | -0.0682 | -0.14 |
| Profit Margin | (0.80) % | (1.27) % |
| Operating Margin | (1.29) % | (5.51) % |
| Current Valuation | 1.69 B | 16.62 B |
| Shares Outstanding | 150.41 M | 571.82 M |
| Shares Owned By Institutions | 15.97 % | 39.21 % |
| Number Of Shares Shorted | 1.63 M | 4.71 M |
| Price To Earning | 4.52 X | 28.72 X |
| Price To Book | 51.56 X | 9.51 X |
| Price To Sales | 11.50 X | 11.42 X |
| Revenue | 238.28 M | 9.43 B |
| Gross Profit | 229.65 M | 27.38 B |
| EBITDA | (97.74 M) | 3.9 B |
| Net Income | (189.73 M) | 570.98 M |
| Cash And Equivalents | 726.83 M | 2.7 B |
| Cash Per Share | 5.32 X | 5.01 X |
| Total Debt | 635.93 M | 5.32 B |
| Debt To Equity | 2.31 % | 48.70 % |
| Current Ratio | 2.98 X | 2.16 X |
| Book Value Per Share | 1.30 X | 1.93 K |
| Cash Flow From Operations | (295.84 M) | 971.22 M |
| Short Ratio | 4.54 X | 4.00 X |
| Earnings Per Share | (1.47) X | 3.12 X |
| Target Price | 15.29 | |
| Number Of Employees | 524 | 18.84 K |
| Beta | 0.6 | -0.15 |
| Market Capitalization | 2.71 B | 19.03 B |
| Total Asset | 2.03 B | 29.47 B |
| Retained Earnings | (1.01 B) | 9.33 B |
| Working Capital | 549.71 M | 1.48 B |
| Current Asset | 386.7 M | 9.34 B |
| Current Liabilities | 48.64 M | 7.9 B |
MorphoSys Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as MorphoSys . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About MorphoSys Buy or Sell Advice
When is the right time to buy or sell MorphoSys AG ADR? Buying financial instruments such as MorphoSys Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Stockholder Equity | 244.9M | 157.4M | 49.0M | 46.6M | Total Current Liabilities | 284.5M | 278.3M | 264.3M | 277.5M |
Use Investing Ideas to Build Portfolios
In addition to having MorphoSys in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Robots And Drones Thematic Idea Now
Robots And Drones
Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. The Robots And Drones theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Robots And Drones Theme or any other thematic opportunities.
| View All Next | Launch |
Check out MorphoSys Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for MorphoSys Stock analysis
When running MorphoSys' price analysis, check to measure MorphoSys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MorphoSys is operating at the current time. Most of MorphoSys' value examination focuses on studying past and present price action to predict the probability of MorphoSys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MorphoSys' price. Additionally, you may evaluate how the addition of MorphoSys to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is MorphoSys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MorphoSys. If investors know MorphoSys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MorphoSys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share (1.47) | Revenue Per Share 1.736 | Quarterly Revenue Growth (0.28) | Return On Assets (0.07) |
The market value of MorphoSys AG ADR is measured differently than its book value, which is the value of MorphoSys that is recorded on the company's balance sheet. Investors also form their own opinion of MorphoSys' value that differs from its market value or its book value, called intrinsic value, which is MorphoSys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MorphoSys' market value can be influenced by many factors that don't directly affect MorphoSys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MorphoSys' value and its price as these two are different measures arrived at by different means. Investors typically determine if MorphoSys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MorphoSys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.